Cambridge Healthtech Institute’s 17th Annual
Advancing Multispecifics and Combination Therapy to the Clinic
Novel and Synergistic Combinations
12 November 2025
A rapidly growing repertoire of multispecific antibodies is being created with greater functionality and efficacy than ever before and has become the dominant and preferred modality in the antibody drug marketplace. Cambridge Healthtech Institute's Seventeenth Annual Advancing Multispecific Antibodies and Combination Therapy track at PEGS Europe will bring together the leading players in the field to disclose the latest preclinical and clinical results of these novel constructs and assess their viability. Best practices for translation and optimization of candidates will be shared through case studies and examples.
Coverage will include, but is not limited to:
- Determining developability parameters
- Advancing co-stimulatory mulitspecific antibodies
- Reviewing preclinical and clinical results
- Designing novel T-cell engaging bispecific antibodies for oncology and autoimmune diseases
- Engineering conditionally active multispecific antibodies
- Demonstrating effector cell redirection
- Addressing clinical unmet needs with bispecifics
- Understanding non-responders vs responders for multispecifics
- Molecular imaging of multispecifics
The deadline for priority consideration is 28 March 2025.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: